Loading
In squamous non-small-cell lung cancer that had progressed after platinum chemotherapy, the PD-1 antibody nivolumab prolonged life compared with docetaxel with far fewer severe side effects, regardless of PD-L1 status.
CheckMate 017 randomised 272 patients with advanced squamous non-small-cell lung cancer that had progressed during or after first-line platinum chemotherapy to nivolumab or docetaxel. Nivolumab improved overall survival, the primary endpoint, as well as response rate and progression-free survival, with a fraction of the grade 3 or 4 toxicity of docetaxel. Unlike its non-squamous companion trial CheckMate 057, the benefit did not depend on PD-L1 expression, which led to nivolumab's approval in squamous disease without a biomarker requirement.
With CheckMate 057 this trial ended docetaxel's role as the default second-line treatment in lung cancer and gave the first phase 3 proof that PD-1 blockade extends life in a common carcinoma. Its PD-L1-independent benefit in squamous disease still shapes how the biomarker is used.
Shares Make six-weekly immunotherapy the default schedule, Restore weight-based dosing and vial sharing for immunotherapy in the label, Give subcutaneous immunotherapy in community clinics and at home, Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch.
Shares CheckMate 057: nivolumab beats docetaxel after chemotherapy in non-squamous lung cancer, Overall survival (OS), Docetaxel, PD-L1.
Shares Bristol Myers Squibb, Docetaxel, PD-L1, Nivolumab.
Shares CheckMate 057: nivolumab beats docetaxel after chemotherapy in non-squamous lung cancer, Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch, Overall survival (OS), PD-L1.
Shares Bristol Myers Squibb, Docetaxel, PD-L1, Nivolumab.
Shares Objective response rate (ORR), Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch, PD-L1, PD-1.
Shares Make six-weekly immunotherapy the default schedule, Restore weight-based dosing and vial sharing for immunotherapy in the label, Overall survival (OS), PD-1.
Shares Julie R. Brahmer, Objective response rate (ORR), Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch, Bristol Myers Squibb.